AstellasPharma Korea, Inc. is the Korean subsidiary of a leading global pharmaceutical company with outstanding R&D capabilities and a worldwide network. It was founded on April 1st, 2005, through a merger between Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd., using 100% Japanese funding and dedicated to the goal of continued increase in company value.
Astellas has contributed to increasing the quality of life of customers by developing drugs to treat adult diseases and disorders such as urination disturbances common in men, frequent urination commonly in women, over active bladder syndrome that causes frequent bathroom trips, as well as painful atopic dermatitis. The company also developed Prograf and Advagraf, and immunosuppression agent, which has improved the survival rate of organ transplant recipients.
AstellasPharma Korea has been growing as a firm, taking pride in its contributions to customer quality of life, and provision of premium medicines in Korea, including Prograf, Advagraf, Harnal, Vesicareand Protopic Ointment. It also a promising company in the mid-to-long term with many superb products awaiting further development, clinical testing, and launch. AstellasPharma Korea does not aim to merely expand sales volume, but will continuously increase company value with the goal of maximizing added value for customers and those seeking better health, by establishing its Global Category Leader business model.
Since the foundation, for the past 70 years, Chong Kun Dang only made pharmacies based on the dignity of human lives, Chong Kun Dang has set up implementation of healthy society without diseases as the company ideology while making better pharmacy.
This is the value that will never change as long as Chong Kun Dang exists as a pharmacy company.
Novartis AG, headquartered in Basel, Switzerland, is a leading global innovation-driven pharmaceutical company which is committed to discover and develop innovative drugs to cure diseases, to ease suffering and to enhance the quality of life through its more than 140 years history. Today, Novartis is one of the fastest growing global pharmaceutical companies, ranking the 2nd largest in the world. Novartis Group companies employ about 100,000 people and operate in over 140 countries. Novartis Korea is an affiliate of Novartis AG.
Roche Korea is a Korean subsidiary of F. Hoffmann-La Roche, a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics, headquartered in Basel, Switzerland.
Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism, CNS and Transplantation. Roche’s transplant treatments are designed to support the long-term survival of transplanted organ. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
Roche employs more than 80,000 people and sells its products in more than 150 countries. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Having spearheaded the biotechnology industry in Korea for the last half century, Green Cross is now evolving into ‘a global leader in healthcare industry’ for a bright future for everyone.
For this, Green Gross promises to you it will put into practice its values: care, compassion, fairness, integrity and respect for all humanity. These are the values embodied by Green Cross on the basis of the spirit of creativity and challenge.